Desk›Healthcare› Aarti Pharmalabs Ltd
Aarti Pharmalabs Ltd
BSE 543748 · NSE AARTIPHARM · ISIN INE0LRU01027 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹839.50
+3.10%
BSE close, 28 August 2026
₹7,612.57 cr
9.1 cr shares · Small cap
₹4,319.94 cr
as published
36.6× · 4.46×
EPS ₹22.95 · BV ₹188.23
1,797.55 / 176.20
₹ cr, as filed
24
8 selected · 33%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -11.3% |
|---|---|
| Against 52-week low | +43.8% |
| Day change | +3.10% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹22.95 |
|---|---|
| Price / earnings | 36.58× |
| Price / book | 4.46× |
| Book value — derived, price ÷ P/B | ₹188.23 |
| Return on equity | 12.19% |
| Operating margin | 26.02% |
| Net margin | 13.34% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 12.19%
- ROE as published
- 12.19%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 534.59 | 71.31 | 7.87 | 26.02% | 13.34% |
| Mar-26 · Q | 579.70 | 62.03 | 6.84 | 22.01% | 10.70% |
| FY25-26 | 1,797.55 | 176.20 | 19.44 | 21.44% | 9.80% |
Quarter on quarter
- Revenue, quarter on quarter
- -7.8%
- Net profit, quarter on quarter
- +15.0%
- Operating margin, quarter on quarter
- +401 bps
Disclosure profile 24 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Change in Directorate | 2 |
| Investor Presentation | 2 |
| Board Outcome | 1 |
| Change in Management | 1 |
| Concall Transcript | 1 |
| Results | 1 |
| Selected sub-total | 8 |
| Procedural | |
| General | 5 |
| AGM / EGM | 2 |
| Analyst / Investor Meet | 2 |
| Board Meeting | 2 |
| Compliance Certificate | 1 |
| Newspaper Publication | 1 |
| Record Date | 1 |
| SAST | 1 |
| Trading Window | 1 |
| Procedural sub-total | 16 |
| Total | 24 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
24 filings · 8 selected · busiest 2026-08-07
Filing rhythm · the twelve most recent
2026-08-312026-10-09
SelectedProcedural
Filings
24 in the window · 4 earlier on record
-
9 October 2026 ·
Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30, 2026
Aarti Pharmalabs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Standalone And Consolidated ....
Board Meeting / Board Meeting View filing →
-
9 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, for the quarter ended September 30, 2026.
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
30 September 2026 ·
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed
Company Update / General View filing →
-
30 September 2026 ·
Intimation Under Regulation 30 Of SEBI Listing Regulations
Please find enclosed
Company Update / General View filing →
-
28 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
23 September 2026 ·
-
23 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Scrutinizers Report and Voting Result of 7th Annual General Meeting
AGM/EGM / AGM View filing →
-
23 September 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gloire Trusteeship Services Pvt Ltd & Others
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
22 September 2026 ·
Investor Presentation
Investor Presentation made at the 7th Annual General Meeting
Company Update / Investor Presentation View filing →
-
22 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 7th Annual General Meeting
AGM/EGM / AGM View filing →
-
2 September 2026 ·
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed
Company Update / General View filing →
-
31 August 2026 ·
-
18 August 2026 ·
-
17 August 2026 ·
Record Date For Dividend For FY 2025-26
Disclosure as enclosed
Corp. Action / Record Date View filing →
-
17 August 2026 ·
Earnings Call Transcript
Q1 FY 27 Earnings Call Transcript
Company Update / Earnings Call Transcript View filing →
-
10 August 2026 ·
Analyst / Investor Meet - Outcome
Audio Recording of Conference Call for Investor and Analysts
Company Update / Analyst / Investor Meet View filing →
-
10 August 2026 ·
Investor Presentation
Q1 FY 2027 Investor Presentation
Company Update / Investor Presentation View filing →
-
7 August 2026 ·
-
7 August 2026 ·
Approved Capacity Addition For Development Of Intermediate Block
Disclosure as enclosed
Company Update / General View filing →
-
7 August 2026 ·
-
7 August 2026 ·
Approval Of Unaudited Financial Results (Standalone And Consolidated)For The Quarter Ended June 30, 2026
Approval of Unaudited Financial Results (Standalone and Consolidated) for the Quarter Ended June 30, 2026
Result / Financial Results View filing →
-
7 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Held On August 07, 2026.
Outcome of Board Meeting held on August 07, 2026.
Board Meeting / Outcome of Board Meeting View filing →
-
3 August 2026 ·
Analyst / Investor Meet - Intimation
This is to inform you that the Earnings Conference Call for investors and analysts has been scheduled for Monday, August 10, 2026, at 4:00 p.m. (IST) to discuss the Company's Q1-FY27 Financial ....
Company Update / Analyst / Investor Meet View filing →
-
28 July 2026 ·
Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2026.
Aarti Pharmalabs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve the unaudited financial results ....
Board Meeting / Board Meeting View filing →
RSS feed for Aarti Pharmalabs Ltd · the 50 most recent filings